1.646.889.1200|info@lifescipublicrelations.com

Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

//Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

Oxurion announced that it entered into a strategic research collaboration with Beta Therapeutics (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration.

By | 2018-11-07T10:50:02-04:00 November 6th, 2018|News|Comments Off on Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.